Last10K.com

Inhibikase Therapeutics, Inc. (IKT) SEC Filing 10-Q Quarterly Report for the period ending Thursday, March 31, 2022

SEC Filings

IKT Quarterly Reports

    10-Q Quarterly Report August 2022
  • 10-Q Quarterly Report May 2022
  • 10-Q Quarterly Report November 2021
    10-Q Quarterly Report August 2021
    10-Q Quarterly Report May 2021

IKT Registration of Securities

Inhibikase Therapeutics, Inc.

CIK: 1750149 Ticker: IKT
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2022
May 02, 2022
Cover [Abstract]  
Document Type10-Q 
Amendment Flagfalse 
Document Period End DateMar. 31, 2022 
Document Fiscal Year Focus2022 
Document Fiscal Period FocusQ1 
Trading SymbolIKT 
Entity Registrant NameINHIBIKASE THERAPEUTICS, INC. 
Entity Central Index Key0001750149 
Current Fiscal Year End Date--12-31 
Entity Filer CategoryNon-accelerated Filer 
Entity Shell Companyfalse 
Entity Small Businesstrue 
Entity Emerging Growth Companytrue 
Entity Ex Transition Periodfalse 
Entity Common Stock, Shares Outstanding 25,227,051
Entity File Number001-39676 
Entity Current Reporting StatusYes 
Entity Tax Identification Number26-3407249 
Entity Address, Address Line One3350 Riverwood Parkway SE 
Entity Address, Address Line TwoSuite 1900 
Entity Address, City or TownAtlanta 
Entity Address, State or ProvinceGA 
Entity Address, Postal Zip Code30339 
City Area Code678 
Local Phone Number392-3419 
Entity Interactive Data CurrentYes 
Title of 12(b) SecurityCommon Stock, $0.001 par value 
Security Exchange NameNASDAQ 
Entity Incorporation, State or Country CodeDE 
Document Quarterly Reporttrue 
Document Transition Reportfalse 

View differences made from one quarter to another to evaluate Inhibikase Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Inhibikase Therapeutics, Inc..

Continue

Assess how Inhibikase Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Inhibikase Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
Other
Filter Subcategory:
All
Cash Flow
Debt
Expense
Geography
Other
Inside Inhibikase Therapeutics, Inc.'s 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Balance Sheets
Condensed Balance Sheets (Parenthetical)
Condensed Statements Of Cash Flows
Condensed Statements Of Operations
Condensed Statements Of Stockholders' Equity
Basis Of Presentation And Significant Accounting Policies
Basis Of Presentation And Significant Accounting Policies (Policies)
Basis Of Presentation And Significant Accounting Policies - Additional Information (Details)
Commitments And Contingencies
Income Taxes
Income Taxes - Additional Information (Details)
Liquidity
Liquidity - Additional Information (Details)
Nature Of Business
Nature Of Business (Additional Information) (Details)
Net Loss Per Share
Net Loss Per Share (Tables)
Net Loss Per Share - Summary Of Calculation Of Basic And Diluted Net Loss Per Share Applicable To Common Stockholders (Details)
Net Loss Per Share - Summary Of Shares Excluded From Calculation Of Diluted Net Loss Per Share Applicable To Common Stockholders (Details)
Notes Payable
Notes Payable - Additional Information (Details)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - Additional Information (Details)
Stock-Based Compensation - Summary Of Stock-Based Compensation Expense For Stock Options Granted To Employees And Non-Employees (Details)
Stockholders' Equity
Stockholders' Equity - Additional Information (Details)
Subsequent Events
Subsequent Events (Additional Information) (Details)
Supplemental Balance Sheet Information
Supplemental Balance Sheet Information (Tables)
Supplemental Balance Sheet Information - Schedule Of Accrued Expenses And Other Current Liabilities (Details)
Warrants
Warrants - Additional Information (Details)

Material Contracts, Statements, Certifications & more

Inhibikase Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: IKT
CIK: 1750149
Form Type: 10-Q Quarterly Report
Accession Number: 0000950170-22-010085
Submitted to the SEC: Mon May 16 2022 4:18:36 PM EST
Accepted by the SEC: Mon May 16 2022
Period: Thursday, March 31, 2022
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/ikt/0000950170-22-010085.htm